Back to Search Start Over

Atezolizumab Plus Bevacizumab in Patients with Advanced and Progressing Hepatocellular Carcinoma: Retrospective Multicenter Experience

Authors :
Friedrich Sinner
Matthias Pinter
Bernhard Scheiner
Thomas Jens Ettrich
Niklas Sturm
Maria A. Gonzalez-Carmona
Oliver Waidmann
Fabian Finkelmeier
Vera Himmelsbach
Enrico N. De Toni
Najib Ben Khaled
Raphael Mohr
Thorben Wilhelm Fründt
Fabian Kütting
Florian van Bömmel
Sabine Lieb
Sebastian Krug
Dominik Bettinger
Michael Schultheiß
Leonie S. Jochheim
Jan Best
Christian Müller
Verena Keitel
Marino Venerito
Source :
Cancers; Volume 14; Issue 23; Pages: 5966
Publication Year :
2022

Abstract

Atezolizumab plus bevacizumab is the standard of care for first-line systemic therapy for advanced hepatocellular carcinoma (aHCC). Data on the efficacy and safety of atezolizumab plus bevacizumab in patients with aHCC who have received prior systemic therapy are not available. Methods: Patients with aHCC who received atezolizumab plus bevacizumab after at least one systemic treatment between December 2018 and March 2022 were retrospectively identified in 13 centers in Germany and Austria. Patient characteristics, tumor response rates, progression-free survival (PFS), overall survival (OS), and adverse events (AE) were analyzed. Results: A total of 50 patients were identified; 41 (82%) were male. The median age at initiation of treatment with atezolizumab plus bevacizumab was 65 years, 41 (82%) patients had cirrhosis, 30 (73%) Child A, 9 (22%) B, and 2 (5%) C. A total of 34 patients (68%) received atezolizumab plus bevacizumab in the second-line setting and 16 (32%) in later lines. The best radiologic tumor responses were complete remission (2%), partial remission (30%), stable disease (36%), and progressive disease (18%), resulting in an objective response rate of 32% and a disease control rate of 68%. Median OS was 16.0 months (95% confidence interval 5.6–26.4 months), and median PFS was 7.1 months (95% confidence interval 4.4–9.8 months). AE grades 3–4 were observed in seven (14%) and resulted in death in three patients (6%). There were five (10%) bleeding events with a grade ≥ 3, including one (2%) with a fatal outcome. Conclusions: Atezolizumab plus bevacizumab is effective in patients with aHCC who did not have access to this option as first-line therapy. The safety profile was consistent with previous reports.

Details

ISSN :
20726694
Volume :
14
Issue :
23
Database :
OpenAIRE
Journal :
Cancers
Accession number :
edsair.doi.dedup.....a345102d55e4aaff41ab1685b0121515